Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
ClinicalTrials.gov · NCT06409130 · Registry updated: 2026-11-19
- Condition / research focus
- Alcohol-related Liver Disease
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- Australia · Bulgaria · Canada · Czechia · Denmark · France · Germany · Greece · Italy · Japan · Netherlands · Poland · Spain · United States
- Registry dates and results
- Start: 2024-05-20. Completion: 2026-01-12 (may be estimated). No results posted in this registry response.
Products and interventions (8)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- NNC0194-0499 (drug)
- Semaglutide (drug)
- NNC0194-0499 placebo (drug)
- Semaglutide placebo (Group A) (drug)
- Cagrilintide + semaglutide (drug)
- Cagrilintide (drug)
- Cagrilintide placebo (drug)
- Semaglutide placebo (Group B) (drug)